4.7 Article

Pharmacological Blockade of 5-HT7 Receptors as a Putative Fast Acting Antidepressant Strategy

期刊

NEUROPSYCHOPHARMACOLOGY
卷 36, 期 6, 页码 1275-1288

出版社

NATURE PUBLISHING GROUP
DOI: 10.1038/npp.2011.13

关键词

mood; anxiety; 5-HT receptors; antidepressant; dorsal raphe; neurogenesis

资金

  1. University Claude Bernard Lyon 1
  2. CNRS
  3. Astra Zeneca
  4. Bristol Myers Squibb
  5. Janssen
  6. Pfizer
  7. Merck Squibb
  8. Merck
  9. Labopharm
  10. Servier
  11. Eli Lilly
  12. Lundbeck
  13. Solvay

向作者/读者索取更多资源

Current antidepressants still display unsatisfactory efficacy and a delayed onset of therapeutic action. Here we show that the pharmacological blockade of serotonin 7 (5-HT7) receptors produced a faster antidepressant-like response than the commonly prescribed antidepressant fluoxetine. In the rat, the selective 5-HT7 receptor antagonist SB-269970 counteracted the anxiogenic-like effect of fluoxetine in the open field and exerted an antidepressant-like effect in the forced swim test. In vivo, 5-HT7 receptors negatively regulate the firing activity of dorsal raphe 5-HT neurons and become desensitized after long-term administration of fluoxetine. In contrast with fluoxetine, a 1-week treatment with SB-269970 did not alter 5-HT firing activity but desensitized cell body 5-HT autoreceptors, enhanced the hippocampal cell proliferation, and counteracted the depressive-like behavior in olfactory bulbectomized rats. Finally, unlike fluoxetine, early-life administration of SB-269970, did not induce anxious/depressive-like behaviors in adulthood. Together, these findings indicate that the 5-HT7 receptor antagonists may represent a new class of antidepressants with faster therapeutic action. Neuropsychopharmacology (2011) 36, 1275-1288; doi: 10.1038/npp.2011.13; published online 16 February 2011

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据